---
run_id: halo-evidence-vs-diagnosis-validation-v12-vanilla-04
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: vanilla
run_number: 4
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 401
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
condition_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
output_file: model-outputs/vanilla-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `vanilla`, run 4 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 401, on the frozen condition packet.

## Output

I recommend you commit to the **Case Evidence Review**.

### The Recommendation
You should tell the CEO that while the top-line numbers look strong, the product is currently suffering from a "perceived value gap." The expansion bookings are driven by pricing incentives (the bundle) and sales promises (the roadmap), not necessarily product utility.

The Case Evidence Review is the only option that solves for the most dangerous signal in your data: **the "Black Box" problem.** The fact that public-sector analysts abandon the tool because they cannot explain the logic to reviewers—and front-line analysts revert to manual notes after two days—suggests that PlanPilot provides a *draft*, but not *confidence*.

If the product cannot be defended by the user to their boss, it is a feature that will be stripped out during procurement (as the regional administrators are already doing). You must determine if PlanPilot is actually solving the workflow or simply providing a template that users feel they have to "fix" manually.

### The Strongest Reason Against It
The Case Evidence Review is a lagging indicator and a manual process. Unlike the Adoption Quality Sprint (which provides real-time dashboards) or the Demand Cleanroom (which tests immediate revenue elasticity), this review will not tell you *how many* people are using the tool or *if* they will pay for it tomorrow. It risks spending precious time on qualitative "forensics" while the sales team continues to sell a version of the product that may not be scalable.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "removal" requests from the regional administrators are based on **budgetary constraints** rather than **utility gaps**.

If those customers say, *"We love the tool, but we can't justify the line-item cost,"* then you have a pricing and packaging problem (solved by the Cleanroom). However, if they say, *"We can't trust the output enough to rely on it for our renewals,"* you have a product-market fit problem that only the Case Evidence Review can diagnose. Given the current signals from public-sector analysts and front-line users, the latter is far more likely.
